Type II Diabetic Subjects Lose Less Weight Than Their Overweight Nondiabetic Spouses

Wing, Ren A R.; Marcus, Marsha P.; Epstein, Leonard H.; Salata, Rose A.

doi:10.2337/diacare.10.5.563

Cited by 188 publications

(164 citation statements)

References 3 publications

Supporting

Mentioning

145

Contrasting

Unclassified

Order By: Relevance

“…It is well known that weight loss is more difficult to achieve in diabetic than nondiabetic patients. 25,26 It can therefore be argued that the addition of HbA1C as a response parameter (as in Switzerland) or a weight loss of less than the Z5% (for example, Z3%) specified for the general obese population in the European label would better define response in obese and overweight type 2 diabetics. The assumptions were tested in a sensitivity analysis.…”

Section: Discussionmentioning

confidence: 99%

Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland

et al. 2005

View full text Add to dashboard Cite

OBJECTIVE:The aim of this study is to review the clinical and economic rationale for the reimbursement of orlistat in responding obese patients with type 2 diabetes. METHODS: Data from seven randomized controlled clinical trials of orlistat in overweight and obese patients with type 2 diabetes were pooled. A subgroup analysis involving patients who achieved a response (defined as a weight loss of Z5% after 12 weeks of treatment) was conducted. The outcomes of the pooled analysis were then used to construct a Markov health economic model covering an 11-y period. The incidences of diabetes-related micro-and macrovascular complications were derived from the United Kingdom Prospective Diabetes Study. The effects of changes in body mass index, and the impact of micro-and macrovascular complications on utilities were derived from published sources. Publicly available cost data were used and are presented here in 2001 Euros. Discounting of 3% was applied. A probabilistic sensitivity analysis was conducted to examine the robustness of results. RESULTS: A total of 1249 patients treated with orlistat and 1230 given placebo were eligible for the intent-to-treat analysis. At the end of the study period, 23% of orlistat patients achieved a weight reduction of Z5%. These patients showed a mean decrease in HbA1C of 1.16%, a weight reduction of 8.6 kg, a reduction in total cholesterol of 5.3% and a reduction in systolic blood pressure of 5.2 mmHg. The base-case economic analysis revealed costs per quality-adjusted life year gained of h14 000 in Sweden and h13 600 in Switzerland. CONCLUSION: The data presented here support the utilization and reimbursement of orlistat in overweight and obese diabetic patients who respond to the treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland

et al. 2005

View full text Add to dashboard Cite

show abstract

“…13,36,37 Many of the patients in this study had comorbid conditions associated with obesity such as hypertension, type II diabetes mellitus, and dyslipidaemia. The lower percentage weight loss seen especially in patients with diabetic comorbidities at baseline is a well-known phenomenon 38 and related to the fact that diabetic patients, in particular, are on concomitant medications that tend to increase body weight. Hence, the weight loss seen in this subgroup (8.5 vs 9.9% in the nondiabetic subgroup) is both clinically relevant and important, especially considering the short (12 weeks) duration of this study, and exceeded that seen previously over a similar period in double-blind, placebocontrolled studies conducted with sibutramine 15 mg. [39][40][41][42] In contrast to the results of controlled clinical trials in which a slight, insignificant increase in mean blood pressure was found 43,44 or a slight reduction in blood pressure only in the weight-loss responders group was found, 45 in this study, we recorded a small but significant decline in both systolic and diastolic blood pressure.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study

Gaciong

Placha

2005

J Hum Hypertens

View full text Add to dashboard Cite

This study aims to determine the efficacy and tolerability of sibutramine hydrochloride in overweight and obese patients with cardiovascular risk factors. This was a 12-week, open-label, observational trial carried out in primary care settings. Patients' data were obtained from questionnaires received from 153 physicians. A total of 2225 overweight and obese (BMIX27 kg/m 2 ) patients received sibutramine in single daily doses of 10 and/or 15 mg. The study population included patients in general good health and with controlled hypertension (41.2%), type II diabetes mellitus (15.6%), hyperlipidaemia (45.5%), and who were chronic tobacco users (smokers) (37.0%). The main outcome measures were changes in body weight, blood pressure and heart rate, and evaluation of reported adverse events. Reduction of body weight of at least 45% from baseline to week 12 was achieved in 2030 (91%) patients and 410% was achieved in 987 (44%) patients. Baseline differences in the percentages of male and female patients, presence or absence of hyperlipidaemia or smoking status did not appear to affect the rate of weight change. Weight loss was less in patients with type II diabetes mellitus and/or controlled systolic hypertension at baseline compared to those patients without these conditions. Mean systolic and diastolic blood pressure and heart rate decreased from baseline to week 12. Overall, sibutramine was well tolerated. In conclusions, treatment with sibutramine resulted in clinically significant weight loss during short-term therapy in obese adults with a range of cardiovascular risk factors.

show abstract

“…Reaching and maintaining acceptable body weight is more difficult in overweight/obese patients with T2DM 17 . Among other factors, hyperinsulinaemia may contribute to this phenomenon via the antilipolytic and anabolic effects of the hormone 8 .…”

Section: Impact Of Glucose Control On Body Weight Regulationmentioning

confidence: 99%

Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes

Scheen

Gaal

2014

The Lancet Diabetes & Endocrinology

175

131

View full text Add to dashboard Cite

New glucose-lowering therapies, especially glucagon-like peptide-1 receptor agonists and sodium glucose cotransporter-2 inhibitors, offer advantages over traditional antidiabetic agents by promoting weight loss while improving glucose control. . The present review will explore the overlapping pathophysiology and also how the various therapies can, alone or in combination, combat the 'dual burden' of obesity and T2DM. Word count: 249

show abstract

Type II Diabetic Subjects Lose Less Weight Than Their Overweight Nondiabetic Spouses

Cited by 188 publications

References 3 publications

Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland

Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland

Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study

Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes

Contact Info

Product

Resources

About